# US 2020/0102344 A1 · Certain chemical entities, compositions, and methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0102344 A1
- Document ID: US20200102344A1
- Status: Published application
- Kind: A1
- Application number: 16/595,749
- Filed: 2019-10-08
- Published: 2020-04-02
- Earliest claimed: 2012-04-29
- Assignees: Neupharma, Inc.
- Applicants: NeuPharma, Inc.
- Inventors: Xiangping QIAN
- Web page: https://patentgrep.com/patent/US20200102344A1

## CPC

- C07J 41/0011: {Unsubstituted amino radicals}
- A61P 35/00: Antineoplastic agents
- C07J 19/00: Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 by a lactone ring
- C07J 41/0005: {the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton}
- C07J 43/003: {not condensed}
- C07J 71/0021: {at position 14(15)}
- C07J: STEROIDS (seco-steroids C07C)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Chemical entities that are novel compounds, pharmaceutical compositions and methods of treatment of cancer are described.

## Claims

### Claim at position 1

-58. (canceled)

### Claim 59

A compound selected from the group consisting of:
N-((3S,5R,8R,9S,10S,13R,14S,17R)-14-hydroxy-10,13-dimethyl-17-(2-oxo-2H-pyran-5-yl)hexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)morpholine-4-carboxamide;
N-((3R,5R,8R,95,10S,13R,14S,17R)-14-hydroxy-10,13-dimethyl-17-(2-oxo-2H-pyran-5-yl)hexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)piperazine-1-carboxamide;
N-((3S,5R,8R,9S,10S,13R,14S,17R)-14-hydroxy-10,13-dimethyl-17-(2-oxo-2H-pyran-5-yl)hexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)piperazine-1-carboxamide;
N-((3S,5R,8R,9S,10S,13R,14S,17R)-14-hydroxy-10,13-dimethyl-17-(2-oxo-2H-pyran-5-yl)hexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)pyrrolidine-1-carboxamide;
1-((3S,5R,8R,9S,10S,13R,14S,17R)-14-hydroxy-10,13-dimethyl-17-(2-oxo-2H-pyran-5-yl)hexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)-3-(2-hydroxyethyl)urea;
1-(2-aminoethyl)-3-((3S,5R,8R,9S,10S,13R,14S,17R)-14-hydroxy-10,13-dimethyl-17-(2-oxo-2H-pyran-5-yl)hexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)urea;
2-amino-N-((3R,5R,8R,95,10S,13R,14S,17R)-14-hydroxy-10,13-dimethyl-17-(2-oxo-2H-pyran-5-yl)hexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)acetamide;
2-amino-N-((3S,5R,8R,9S,10S,13R,14S,17R)-14-hydroxy-10,13-dimethyl-17-(2-oxo-2H-pyran-5-yl)hexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)acetamide;
(S)—N-((3S,5R,8R,9S,10S,13R,14S,17R)-14-hydroxy-10,13-dimethyl-17-(2-oxo-2H-pyran-5-yl)hexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)pyrrolidine-2-carboxamide;
5-((5R,8R,95,10S,13R,14S,17R)-14-hydroxy-10,13-dimethyl-3-(piperazin-1-yl)hexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2H-pyran-2-one;
N-((3S,5R,8R,9S,10S,13R,14S,17R)-14-hydroxy-10,13-dimethyl-17-(2-oxo-2H-pyran-5-yl)hexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)methanesulfonamide;
methyl ((3S,5R,8R,9S,10S,13R,14S,17R)-14-hydroxy-10,13-dimethyl-17-(2-oxo-2H-pyran-5-yl)hexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)carbamate;
methyl ((5R,8R,9S,10S,13R,14S,17R)-14-hydroxy-10,13-dimethyl-17-(2-oxo-2H-pyran-5-yl)hexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)(methyl)carbamate;
(R)-2-amino-N-((3S,5R,8R,95,10S,13R,14S,17R)-14-hydroxy-10,13-dimethyl-17-(2-oxo-2H-pyran-5-yl)hexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)-3-methylbutanamide;
(R)-2-amino-N-((3S,5R,8R,95,10S,13R,14S,17R)-14-hydroxy-10,13-dimethyl-17-(2-oxo-2H-pyran-5-yl)hexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)propanamide;
N-((5S,8R,9S,10R,13R,14S,17R)-5,14-dihydroxy-10,13-dimethyl-17-(2-oxo-2H-pyran-5-yl)hexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)morpholine-4-carboxamide; and
(2R)—N-((5S,8R,9S,10R,13R,14S,17R)-5,14-dihydroxy-10,13-dimethyl-17-(2-oxo-2H-pyran-5-yl)hexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)pyrrolidine-2-carboxamide;
or a pharmaceutically acceptable salt thereof.

### Claim 60 (depends on 59)

The compound of claim 59, wherein the compound is: N-((3S,5R,8R,9S,10S,13R,14S,17R)-14-hydroxy-10,13-dimethyl-17-(2-oxo-2H-pyran-5-yl)hexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)morpholine-4-carboxamide, or a pharmaceutically acceptable salt thereof.

### Claim 61 (depends on 59)

The compound of claim 59, wherein the compound is: N-((3R,5R,8R,95,10S,13R,14S,17R)-14-hydroxy-10,13-dimethyl-17-(2-oxo-2H-pyran-5-yl)hexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)piperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

### Claim 62 (depends on 59)

The compound of claim 59, wherein the compound is: N-((3S,5R,8R,9S,10S,13R,14S,17R)-14-hydroxy-10,13-dimethyl-17-(2-oxo-2H-pyran-5-yl)hexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)piperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

### Claim 63 (depends on 59)

The compound of claim 59, wherein the compound is: N-((3S,5R,8R,9S,10S,13R,14S,17R)-14-hydroxy-10,13-dimethyl-17-(2-oxo-2H-pyran-5-yl)hexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)pyrrolidine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

### Claim 64 (depends on 59)

The compound of claim 59, wherein the compound is: 1-((3S,5R,8R,9S,10S,13R,14S,17R)-14-hydroxy-10,13-dimethyl-17-(2-oxo-2H-pyran-5-yl)hexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)-3-(2-hydroxyethyl)urea, or a pharmaceutically acceptable salt thereof.

### Claim 65 (depends on 59)

The compound of claim 59, wherein the compound is: 1-(2-aminoethyl)-3-((3S,5R,8R,9 S, 10S,13R,14S,17R)-14-hydroxy-10,13-dimethyl-17-(2-oxo-2H-pyran-5-yl)hexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)urea, or a pharmaceutically acceptable salt thereof.

### Claim 66 (depends on 59)

The compound of claim 59, wherein the compound is: 2-amino-N-((3R,5R,8R,95,10S,13R,14S,17R)-14-hydroxy-10,13-dimethyl-17-(2-oxo-2H-pyran-5-yl)hexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)acetamide, or a pharmaceutically acceptable salt thereof.

### Claim 67 (depends on 59)

The compound of claim 59, wherein the compound is: 2-amino-N-((3S,5R,8R,9 S, 10S,13R,14S,17R)-14-hydroxy-10,13-dimethyl-17-(2-oxo-2H-pyran-5-yl)hexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)acetamide, or a pharmaceutically acceptable salt thereof.

### Claim 68 (depends on 59)

The compound of claim 59, wherein the compound is: (S)—N-((3S,5R,8R,9 S, 10S,13R,14S,17R)-14-hydroxy-10,13-dimethyl-17-(2-oxo-2H-pyran-5-yl)hexadecahydro-1H-cyclopenta [a]phenanthren-3-yl)pyrrolidine-2-carboxamide, or a pharmaceutically acceptable salt thereof.

### Claim 69 (depends on 59)

The compound of claim 59, wherein the compound is: 5-((5R,8R,9S,10S,13R,14S,17R)-14-hydroxy-10,13-dimethyl-3-(piperazin-1-yl)hexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2H-pyran-2-one, or a pharmaceutically acceptable salt thereof.

### Claim 70 (depends on 59)

The compound of claim 59, wherein the compound is: N-((3 S, 5R, 8R,9 S, 10S,13R,14S,17R)-14-hydroxy-10,13-dimethyl-17-(2-oxo-2H-pyran-5-yl)hexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)methanesulfonamide, or a pharmaceutically acceptable salt thereof.

### Claim 71 (depends on 59)

The compound of claim 59, wherein the compound is: methyl ((3S,5R,8R,9 S, 10S,13R,14S,17R)-14-hydroxy-10,13-dimethyl-17-(2-oxo-2H-pyran-5-yl)hexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)carbamate, or a pharmaceutically acceptable salt thereof.

### Claim 72 (depends on 59)

The compound of claim 59, wherein the compound is: methyl ((5R,8R,9S,10S,13R,14S,17R)-14-hydroxy-10,13-dimethyl-17-(2-oxo-2H-pyran-5-yl)hexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)(methyl)carbamate, or a pharmaceutically acceptable salt thereof.

### Claim 73 (depends on 59)

The compound of claim 59, wherein the compound is: (R)-2-amino-N-((3S,5R,8R,9S,10S,13R,14S,17R)-14-hydroxy-10,13-dimethyl-17-(2-oxo-2H-pyran-5-yl)hexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)-3-methylbutanamide, or a pharmaceutically acceptable salt thereof.

### Claim 74 (depends on 59)

The compound of claim 59, wherein the compound is: (R)-2-amino-N-((3S,5R,8R,9S,10S,13R,14S,17R)-14-hydroxy-10,13-dimethyl-17-(2-oxo-2H-pyran-5-yl)hexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)propanamide, or a pharmaceutically acceptable salt thereof.

### Claim 75 (depends on 59)

The compound of claim 59, wherein the compound is: N-((5S,8R,9S,10R,13R,14S,17R)-5,14-dihydroxy-10,13-dimethyl-17-(2-oxo-2H-pyran-5-yl)hexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)morpholine-4-carboxamide, or a pharmaceutically acceptable salt thereof.

### Claim 76 (depends on 59)

The compound of claim 59, wherein the compound is: (2R)—N-((5S,8R,9S,10R,13R,14S,17R)-5,14-dihydroxy-10,13-dimethyl-17-(2-oxo-2H-pyran-5-yl)hexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)pyrrolidine-2-carboxamide, or a pharmaceutically acceptable salt thereof.

### Claim 77 (depends on 59)

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the compound or pharmaceutically acceptable salt of claim 59.

### Claim 78 (depends on 59)

A method of ameliorating symptoms or slowing progression of lung cancer in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of the compound or pharmaceutically acceptable salt of claim 59.
